

Zoono Group Limited (ASX: ZNO)**ASX ANNOUNCEMENT**26th November 2019**Zoono Poultry Update**

Zoono Group Limited (**Company**) (ASX: ZNO) refers to the announcement made earlier today by Apiam Animal Health Limited (ASX: AHX).

As advised to the market in Apiam's announcement, Zoono Poultry Limited is the exclusive global licensee of the Company's proprietary technology and products in the poultry farming sector. Zoono Poultry Limited is an independently owned and controlled company (i.e. the Company has no equity or financial interest in it other than as a consequence of its licence agreement).

The Company has worked cooperatively with Zoono Poultry Limited in the finalisation of its commercial agreements with Apiam. Under its exclusive licence agreement with Zoono Poultry Limited, the Company will supply it, in accordance with the agreed commercial terms, with all of its requirements for Zoono products necessary to fulfil its obligations under the Apiam agreements.

In the short term, the Company does not expect the sales volumes to be commercially significant. However, as indicated by Apiam in its announcement, the Company believes the livestock and poultry sectors offer significant potential sales opportunities for Zoono's products as the customer base becomes increasingly aware of those products as an alternative to other antimicrobial products to manage animal health and disease.

In addition to the above, the sales opportunities for Zoono's products in the livestock and poultry sectors is also evidenced by the positive results received to date from trials involving the use of Zoono's products at over 10 different agri sites in China. The Company should be in a position to update the market further on these field trials in the near future

For further information, please contact:**Zoono Group Limited**

Paul Hyslop
Managing Director/CEO
M: +64 21 659 977
E: paul.hyslop@zoono.com

Paul Ravlich
Chief Financial Officer
M: +64 21 0759 176
E: paul.ravlich@zoono.com

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically-validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'zoono molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria,

viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com